PROCEPT BioRobotics Reports First Quarter 2026 Financial Results
PROCEPT BioRobotics reported an 83.1 million revenue for Q1 2026, a 20% increase from the previous year, driven by strong U.S. system sales and handpiece revenue. However, the company incurred a net loss of 31.6 million, with operating expenses rising to 86.6 million. The introduction of a new software, FirstAssist AI, aims to enhance the capabilities of their robotic systems for urology treatments.
SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) — PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2026.